Loading profile…
Pulling IRS BMF, Form 990 filings, peer benchmarks, programs, people, and grants.
Pulling IRS BMF, Form 990 filings, peer benchmarks, programs, people, and grants.

DBA: N/A
EIN 82-2473513 · Snapshot of IRS recognition, filing currency, financial health, and governance.
Our mission is to enable and finance the development of life-saving genetic medicines for ultra-rare patient populations previously deemed too rare to treat. To realize this, our unique ecosystems facilitates collaboration between world-renowned researchers and clinicians, policy experts and our generous donors. Together, we are fundamentally changing the ultra-Rare Disease experience and burden for millions ofpeople around the world with our discoveries and methods - while bringing hope to patients waiting for a cure.
Principal Officer
Richard Horgan
Total Revenue
$5.3M
FY2024
Total Expenses
$2.3M
FY2024
Net Assets
$6.5M
Program Ratio
91.8%
expenses on programs
Employees
9
Volunteers
11
Board Members
12
Voting
11
Independent
8 answers compiled from IRS Form 990, BMF, Pub 78, and the Auto-Revocation List.